Concepedia

Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

Anders Granholm, Maj-Brit N. Kjær, Marie Warrer Munch, Sheila Nainan Myatra, Bharath Kumar Tirupakuzhi Vijayaraghavan, Maria Cronhjort, Rebecka Rubenson Wahlin, Stephan M. Jakob, Luca Cioccari, Gitte Kingo Vesterlund,

Intensive Care Medicine · 2022 · 31 citations · 15 references

DOIFull text

Open access

Concepts

References

15

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

Michael Herdman, Claire Gudex, Andrew Lloyd et al. · Quality of Life Research · 2011 · 10K citations · Full text

, , +16

When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts

Janus Christian Jakobsen, Christian Gluud, Jørn Wetterslev et al. · BMC Medical Research Methodology · 2017 · 2.8K citations · Full text

, , +16

A living WHO guideline on drugs for covid-19 (2020-2023)

Arnav Agarwal, Beverley J. Hunt, Miriam Stegemann et al. · BMJ · 2020 · 1.1K citations · Full text

, , +17

German Value Set for the EQ-5D-5L

Kristina Ludwig, J.-Matthias Graf von der Schulenburg, Wolfgang Greiner · PharmacoEconomics · 2018 · 606 citations · Full text

, , +16

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia

Lene Russell, Kis Rønn Uhre, Ann Louise Syraach Lindgaard et al. · JAMA · 2021 · 263 citations · Full text

, , +13